Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
ICCC · Nasdaq · United States · In Vitro & In Vivo Diagnostic Substances
In shortIMMUCELL CORP /DE/ is loss-making, generates cash and carries moderate debt, with revenue growing (+4.3% last year).
Financial health
Weak
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | 6.0% | 37/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | -3.8% | 5/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | -3.8% | 0/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | 3.6% | 24/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 4.26× | 100/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.34× | 92/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | 1.19× | 80/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | 3.34× | 18/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | 2.93 | 47/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 4.4% | 38/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | – | n/a |
| Years with positive free cash flow (last 5) | 1 of 5 | 0/100 |
Weight in the score: 20%
| Profitable years (last 5) | 0 of 5 | 0/100 |
|---|---|---|
| Years of revenue decline (last 5) | 2 of 5 | 33/100 |
| Revenue growth volatility | 24.2% | 21/100 |
| Operating margin volatility | 15.2% | 0/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 14.2% | 95/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 19 | 19 | 17 | 26 | 28 |
| Cost of revenue | 11 | 11 | 14 | 19 | 16 |
| Gross profit | 8.7 | 7.6 | 3.9 | 7.9 | 11 |
| Research & development | 4.2 | 4.5 | 4.4 | 3.9 | 3 |
| Operating income | 0.3 | (2.3) | (5.7) | (1.6) | 1.6 |
| Interest expense | 0.3 | 0.3 | 0.5 | 0.6 | 0.5 |
| Pre-tax income | (0.1) | (2.5) | (5.8) | (2.1) | (1) |
| Income tax | 0 | 0 | 0 | 0 | 0 |
| Net income | (0.1) | (2.5) | (5.8) | (2.2) | (1) |
| Diluted EPS | −$0.01 | −$0.32 | −$0.75 | −$0.26 | −$0.12 |
| Diluted shares (millions) | 7.6 | 7.7 | 7.7 | 8.2 | 9 |
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 8 reported quarters (10-Q and 10-K filings), in USD millions. The fourth quarter is derived from the annual report.
The last 8 quarters of IMMUCELL CORP /DE/ are included in the Investor plan. Try free for 7 days →
2.93 Safe zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
7/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 30, 2026 · Data updated Aug 13, 2026